Review clinical trials related to Oncolytic Virus. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.
This study evaluates H101 combined with transarterial chemoembolization (TACE) to enhance local tumor killing and immune activation while minimizing toxicity in r/m HNSCC patients.
Age between 18 and under 80 years old. [+6]
Expected survival less than 3 months. [+9]
This is a single-arm, single-center, drug safety assessment clinical trial with a 3+3 dose escalation design, to observe the safety, tolerability and toxicity of a novel oncolytic virus Ad-TD-nsIL12 intratumoral injection in progressive DIPG patients (NCI-CTCAE V5.0).
Informed consent of the parents or patient. [+7]
Serious infections or intercurrent conditions, including but not limited to seve... [+13]
This is a drug safety assessment clinical trial with a 3+3 dose escalation design, to observe the safety, tolerability and toxicity of a novel oncolytic virus Ad-TD-nsIL12 intratumoral injection in primary DIPG patients (NCI-CTCAE V5.0).
Informed consent of the parents or patient. [+7]
Serious infections or intercurrent conditions, including but not limited to seve... [+13]